CPC A01K 67/0278 (2013.01) [A01K 67/0276 (2013.01); A01K 2207/15 (2013.01); A01K 2217/052 (2013.01); A01K 2217/072 (2013.01); A01K 2217/075 (2013.01); A01K 2217/15 (2013.01); A01K 2227/105 (2013.01); A01K 2267/01 (2013.01); A61K 49/0008 (2013.01); C07K 14/524 (2013.01); C07K 14/535 (2013.01); C07K 14/5403 (2013.01); C07K 14/5412 (2013.01)] | 11 Claims |
1. A method of screening a candidate agent for the ability to treat a hematopoietic cancer, the method comprising,
contacting a first genetically modified, immunodeficient mouse with a candidate agent, wherein the first genetically modified, immunodeficient mouse is a Rag-2−/−IL-2rgnull mouse comprising
a genome comprising a nucleic acid encoding human IL-6, wherein the nucleic acid encoding human IL-6 replaces the endogenous mouse IL-6 gene at the endogenous mouse IL-6 gene locus, and wherein the nucleic acid encoding human IL-6 is operably linked to the endogenous mouse IL-6 promoter, and
an engraftment of human hematopoietic cancer cells; and
comparing the viability and/or proliferative rate of human hematopoietic cancer cells in the contacted first genetically modified, immunodeficient mouse to the viability and/or proliferative rate of human hematopoietic cancer cells in a second genetically modified, immunodeficient mouse not contacted with the candidate agent, wherein the second genetically modified, immunodeficient mouse is a Rag-2−/−IL-2rgnull mouse comprising
a genome comprising a nucleic acid encoding human IL-6, wherein the nucleic acid encoding human IL-6 replaces the endogenous mouse IL-6 gene at the endogenous mouse IL-6 gene locus, and wherein the nucleic acid encoding human IL-6 is operably linked to the endogenous mouse IL-6 promoter, and
an engraftment of human hematopoietic cancer cells,
wherein a decrease in the viability and/or rate of proliferation of the human hematopoietic cancer cells in the contacted first genetically modified,
immunodeficient mouse is indicative of the ability of the candidate agent to treat the hematopoietic cancer.
|